Donor Specific Antibodies in Extracorporeal Membrane Oxygenation-Bridged Lung Transplant Recipients

Background

Extracorporeal membrane oxygenation (ECMO) is increasingly used as a bridge to lung transplantation. Although other mechanical circulatory support devices have been associated with anti-human leukocyte antigen antibody formation, including de novo donor-specific antibodies (dnDSA), it is unknown whether ECMO is a sensitizing exposure.

Methods

This was a single-center retrospective cohort study of lung transplant recipients. We compared dnDSA development in ECMO-bridged and non-ECMO exposed recipients. We also assessed differences in chronic lung allograft dysfunction-free survival between ECMO-bridged recipients with and without dnDSA, and between those who developed dnDSA with and without ECMO bridge.

Results

Among 299 transplant recipients, 48 were ECMO-bridged and 251 were non-ECMO exposed. dnDSA developed in 33.3% of ECMO-bridged and 21.5% of non-ECMO exposed recipients. ECMO was associated with dnDSA development in bivariate (hazard ratio [HR], 2.08, 95% CI, 1.19-3.64, P = .01) but not multivariate analysis after adjusting for known confounders (HR, 1.10, 95% CI, 0.50-2.42, P = .82). Higher posttransplant transfusion volume was independently associated with dnDSA development (HR, 4.68, 95% CI, 2.25-9.72, P < .001). ECMO-bridged recipients with dnDSA did not have worse adjusted chronic lung allograft dysfunction-free survival than those without dnDSA (HR, 0.35, 95% CI, 0.07-1.87, P = .22) or compared to non-ECMO exposed recipients with dnDSA (HR, 0.40, 95% CI, 0.08-2.00, P = .27).

Conclusions

A more restrictive posttransplant transfusion threshold among ECMO-bridged lung transplant recipients may reduce the risk of dnDSA. Surveillance for dnDSA, at least among ECMO-bridged recipients, may only be necessary in the presence of allograft dysfunction.